Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.
Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL) plans to discuss third-quarter 2026 financial results during a conference call and webcast on November 9, 2026. The call is scheduled for 8:00 AM ET and will cover recent business progress and the quarter ended September 30, 2026. The webcast will be available through the company's Investor Relations page, with a replay archived for at least 30 days.
Ocular Therapeutix (OCUL) will participate in investor and scientific conferences during November 2026, including a UBS fireside chat in London. CEO Pravin U. Dugel will speak on November 17, with a webcast and replay available for at least 30 days. Scientific appearances in New York include The Empire Forum on November 5 and an OSN symposium on November 7. Medical conference presentation times may change.
Ocular Therapeutix (OCUL) granted inducement equity awards to fifteen newly hired non-executive employees, effective October 5, 2026.
The grants comprise stock options to purchase up to 70,150 common shares and restricted stock units representing the right to receive 22,900 common shares. The options have a $7.25 per-share exercise price, equal to the closing share price on the grant date, and a ten-year term. The awards were made under the 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as a material inducement to each recipient’s acceptance of employment.
Ocular Therapeutix (NASDAQ: OCUL) will participate in scientific conferences and an investor conference during October 2026 in New Orleans and New York. CEO Pravin U. Dugel will present a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20 at 9:45 AM ET in New York.
Scientific appearances in New Orleans include Eyecelerator and Innovate Retina on October 8, followed by American Academy of Ophthalmology meetings. Scheduled presentations on October 8, 9 and 12 cover the Phase 3 SOL-1 trial; the announcement provides no trial results. Medical conference presentation times may change. The Chardan webcast will be available through the company's investor relations website, with a replay archived for at least 30 days.
Ocular Therapeutix (OCUL) granted inducement equity awards to nine newly hired non-executive employees effective September 14, 2026, under its 2019 Inducement Stock Incentive Plan and Nasdaq Listing Rule 5635(c)(4).
The awards comprise non-statutory stock options for up to an aggregate of 64,850 shares and restricted stock units (RSUs) for an aggregate of 21,350 shares of common stock. The stock options have a ten-year term and an exercise price of $10.72 per share, equal to the Nasdaq Global Market closing price on the grant date. Options vest over four years, with 25% after one year and the remainder in equal monthly installments over the next three years, subject to continued service. RSUs vest in three equal annual installments over three years, also subject to continued service and the terms of the award agreements and plan.
Ocular Therapeutix (OCUL) completed a positive Pre-New Drug Application (Pre-NDA) meeting with the U.S. FDA for AXPAXLI™ (OTX-TKI) in wet age-related macular degeneration and remains on track to submit an NDA in the fourth quarter of 2026.
The FDA indicated alignment with an NDA package based on Week 52 efficacy and safety data from the registrational Phase 3 SOL-1 trial, interim safety data from the ongoing Phase 3 SOL-R trial, and supporting confirmatory evidence, including subjects who have received multiple AXPAXLI injections to support repeat dosing. SOL-1, conducted under a Special Protocol Assessment, met its pre-specified primary endpoint with high statistical significance in February 2026. The planned submission will use the 505(b)(2) pathway, which the company states may shorten the FDA review timeline by up to 60 days compared with the 505(b)(1) pathway, and commercial preparations are advancing ahead of a potential 2027 launch.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple investor and scientific conferences in September and October 2026, including Wells Fargo and Baird healthcare investor events with a webcasted fireside chat, and several retina-focused meetings where Phase 3 SOL-1 trial results for OTX-TKI in neovascular AMD will be presented.
Ocular Therapeutix (NASDAQ: OCUL) granted equity inducement awards to its new SVP, Government Affairs and Public Policy, Beth Rada, under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards, effective August 10, 2026, include a non-statutory option to purchase up to 85,000 shares at an exercise price of $9.24 per share, with a ten-year term and four-year vesting schedule, and restricted stock units covering 28,000 shares vesting in three equal annual installments, all subject to continued service and applicable award agreement terms.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, effective August 3, 2026, in line with Nasdaq Listing Rule 5635(c)(4).
The grants cover non-statutory stock options for up to 53,975 shares at an exercise price of $8.40 per share with a ten-year term, plus restricted stock units for 17,450 shares. Options vest over four years (25% after one year, then monthly for three years) and RSUs vest in three equal annual installments, all subject to continued service.
Ocular Therapeutix (NASDAQ: OCUL) reported second quarter 2026 results and detailed progress on its AXPAXLI (OTX-TKI) retina franchise. According to Ocular Therapeutix, an NDA for AXPAXLI in wet AMD is planned for Q4 2026 under the Section 505(b)(2) pathway, following a positive FDA Type C meeting and a pre-NDA meeting scheduled for Q3 2026. The filing will rely on SOL-1 Week 52 efficacy and safety data plus interim SOL-R safety data, targeting an aggregate safety set of over 300 patients with at least one year of exposure.
A post-hoc SOL-1 analysis suggested up to an estimated 72% reduction in treatment burden versus projected on-label aflibercept (2 mg) over 60 weeks. Cash and equivalents were $598.6 million at June 30, 2026, with projected runway into 2028. Q2 2026 net revenue was $13.5 million, flat year over year, and net loss was $(78.8) million, or $(0.35) per share, as R&D, selling and marketing, and G&A expenses all increased to support Phase 3 trials and commercial readiness for a potential 2027 launch, if approved.